Investors will love Johnson & Johnson's commitment to dividend payments. Vertex Pharmaceuticals already delivers billion-dollar earnings -- and new programs could further lift growth.
Warren Buffett is a defensive investor at heart. As a result, the Oracle of Omaha places a premium on the sustainability of a company's profits over long periods of time.

May Dogs Of The Dow: Buy 2, Watch 4

07:12pm, Wednesday, 10'th May 2023
"The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” -
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, at the Waldorf Astoria Monarch

Pharma ETFs Gain Post Q1 Earnings

01:01pm, Tuesday, 09'th May 2023
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
This year hasn't been the most active when it comes to initial public offerings, but Johnson & Johnson NYSE: JNJ spinoff Kenvue Inc. NYSE: KVUE set a bar, of sorts, with the biggest IPO since Rivian A
After a relatively impressive 2022, the best healthcare dividend stocks have hit a temporary rough patch this year. However, savvy investors shouldn't let this blip deter them from wagering on this de
Many investors do not consider Peter Lynch to be a dividend investor – an unfortunate misunderstanding in my view. He has so many valuable insights into dividend stocks. It is just these insights ar
Communications from management tend to be quite optimistic. Controversies aren't always a valid reason to sell your shares.
We also look at Darden Restaurants' acquisition and Yum! Brands' quarter.
Short sellers aren't afraid of many stocks in the S&P 500. But one stock they won't touch is Warren Buffett's Berkshire Hathaway.
There's still time for investors to take advantage of the latest dividend bumps. A spinoff, along with the dividend hike, provide new reasons to like Johnson & Johnson stock.
Johnson & Johnson has spun-off its consumer health business called Kenvue. The IPO was a modest success, and despite a >$50 billion enterprise valuation, it is not a game changer for Johnson & Johnson
Warren Buffett has a laser-like focus on owning companies with limited competition, stellar management, and sustainable profits. The rare disease specialist Vertex Pharmaceuticals ticks all of these b
This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying and are offering large discounts to their historical norms. We go over
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE